Cargando…
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
BACKGROUND: To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated with a combination of anti-vascular endothelial growth factor and standard-dose photodynamic therapy (PDT). Choroidal...
Autores principales: | Wong, Ian Y., Shi, Xuan, Gangwani, Rita, Zhao, Paul, Iu, Lawrence P., Li, Qing, Ng, Alex, Li, Xiaoxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485362/ https://www.ncbi.nlm.nih.gov/pubmed/26122636 http://dx.doi.org/10.1186/s12886-015-0061-8 |
Ejemplares similares
-
Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
por: Nemoto, Rei, et al.
Publicado: (2012) -
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019) -
Photodynamic therapy for polypoidal choroidal vasculopathy secondary to choroidal nevus
por: Wong, James G, et al.
Publicado: (2017) -
Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017) -
Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)